Skip to main content

Qiagen to Distribute Whatman's DNA-Storage Technology

NEW YORK (GenomeWeb News) — Qiagen said yesterday that it will distribute Whatman's FTA DNA-handling products under a non-exclusive agreement.
 
Under the agreement, Qiagen will pay an upfront fee and royalties for the rights to sell the kits in the life science research, molecular diagnostics, and applied-testing markets.
 
The royalty payments will apply to all Qiagen sales that incorporate Whatman's products.
 
Whatman's FTA instruments and FTA-based kits use "a chemically treated matrix" that lyses cells, immobilizes nucleic acids, and allows researchers to collect, transport, archive, and release DNA at room temperature.
 
Qiagen said the FTA line is "highly synergistic" with its sample-prep technology portfolio, and that it expects the combination of tools to be useful in forensics, pharmacogenomics, biobanking, and genomics research.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.